JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online September 14, 2007, 10.2967/jnumed.107.043414
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.107.043414v1
48/10/1592    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Geus-Oei, L.-F.
Right arrow Articles by Oyen, W. J.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Geus-Oei, L.-F.
Right arrow Articles by Oyen, W. J.G.
Journal of Nuclear Medicine Vol. 48 No. 10 1592-1598
© 2007 by Society of Nuclear Medicine
doi: 10.2967/jnumed.107.043414

Clinical Investigation

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

Lioe-Fee de Geus-Oei1, Henricus F.M. van der Heijden2, Eric P. Visser1, Rick Hermsen1, Bas A. van Hoorn1, Johanna N.H. Timmer-Bonte2,3, Antoon T. Willemsen4, Jan Pruim4, Frans H.M. Corstens1, Paul F.M. Krabbe5 and Wim J.G. Oyen1

1 Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 2 Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 3 Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 4 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands; and 5 Department of Medical Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Correspondence: For correspondence or reprints contact: Lioe-Fee de Geus-Oei, MD, Department of Nuclear Medicine (internal postal code 444), Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: L.degeus-oei{at}nucmed.umcn.nl

The aim of this prospective study was to evaluate the value of 18F-FDG PET for the assessment of chemotherapy response in patients with non–small cell lung cancer. Furthermore, part of the objective of this study was to compare 2 methods to quantify changes in glucose metabolism. Methods: In 51 patients, dynamic 18F-FDG PET was performed before and at 5–8 wk into treatment. Simplified methods to measure glucose metabolism (standardized uptake value [SUV]) and quantitative measures (metabolic rate of glucose [MRGlu]), derived from Patlak analysis, were evaluated. The overall survival and progression-free survival with respect to MRGlu and SUV were calculated using Kaplan–Meier estimates. Fractional changes in tumor glucose use were stratified by the median value and also the predefined EORTC (European Organization for Research and Treatment of Cancer) metabolic response criteria, and criteria applying cutoff levels similar to those of RECIST (Response Evaluation Criteria in Solid Tumors) were evaluated. Results: When stratifying at the median value of {Delta}MRGlu and {Delta}SUV, the difference in overall survival (P = 0.017 for {Delta}MRGlu, P = 0.018 for {Delta}SUV) and progression-free survival (P = 0.002 for {Delta}MRGlu, P = 0.0009 for {Delta}SUV) was highly significant. When applying the predefined criteria for metabolic response, the cutoff levels as also used for size measurement (RECIST) showed significant differences for {Delta}SUV between response categories in progression-free survival (P = 0.0003) as well as overall survival (P = 0.027). Conclusion: The degree of chemotherapy-induced changes in tumor glucose metabolism as determined by 18F-FDG PET is highly predictive for patient outcome, stratifying patients into groups with widely differing overall survival and progression-free survival probabilities. The use of 18F-FDG PET for therapy monitoring seems clinically feasible, because simplified methods to measure tumor glucose use (SUV) are sufficiently reliable and can replace more complex, quantitative measures (MRGlu) in this patient population.

Key Words: chemotherapy response monitoring • 18F-FDG PET • non–small cell lung cancer • standardized uptake value • Patlak analysis

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2007 48: 11A-12A. [Full Text]  



This article has been cited by other articles:


Home page
 JNMHome page
E. P. Visser, M. E.P. Philippens, L. Kienhorst, J. H.A.M. Kaanders, F. H.M. Corstens, L.-F. de Geus-Oei, and W. J.G. Oyen
Comparison of Tumor Volumes Derived from Glucose Metabolic Rate Maps and SUV Maps in Dynamic 18F-FDG PET
J. Nucl. Med., June 1, 2008; 49(6): 892 - 898.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Plathow and W. A. Weber
Tumor Cell Metabolism Imaging
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.